SOUTH PLAINFIELD, N.J., July 28 PTC Therapeutics, Inc.(PTC) today announced that the company was awarded the Art of IndustryPartnership Award by the Genetic Alliance. Genetic Alliance presents the Artof Listening, Art of Advocacy, and Art of Industry Partnership Awardsannually.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"The Art of Industry Partnership Award honors a for-profit company thatmodels the benefits of creative partnerships between consumer advocates andindustry in advancing understanding and treatment of genetic conditions,"stated Sharon Terry, chief executive of the Genetic Alliance. "PTCTherapeutics has proven itself a leader in establishing productive, effectivepartnerships between government, advocacy organizations and physicians toadvance drug development in areas of high unmet medical need; areas where fewother pharmaceutical companies have been willing to focus. We are proud toacknowledge their leadership with this award."
PTC has established relationships and partnerships with several advocacygroups, including the Muscular Dystrophy Association, the Parent ProjectMuscular Dystrophy, the Cystic Fibrosis Foundation, the Spinal MuscularAtrophy Foundation, and Fight SMA. Collectively these groups have providedsignificant funding to support research in multiple genetic disorders.Importantly, the advocacy community has also been essential in helpingestablishing clinical endpoints and facilitating better understanding thechallenges and needs of those affected by genetic disorders. The result ofthis support is that PTC now has established one of the broadest geneticdisorders pipelines in the industry with over eleven programs addressingDuchenne muscular dystrophy, cystic fibrosis, and spinal muscular atrophy.
"We are honored to receive this award from the Genetic Alliance. Ourrelationships with the advocacy community have been essential in our quest todevelop innovative therapeutics in genetic disorders," stated Stuart W. Peltz,Ph.D., president and chief executive officer of PTC Therapeutics. "We lookforward to continuing these valuable and productive collaborations withadvocacy groups as well as the broader patient community."
About Genetic Alliance
Genetic Alliance transforms health through genetics, using an environmentof openness centered on the health of individuals, families, and communities.Genetic Alliance brings together diverse stakeholders that create novelpartnerships in advocacy; integrates individual, family, and communityperspectives to improve health systems; and revolutionizes access toinformation to enable translation of research into services and individualizeddecision making.
About PTC Therapeutics Inc.
PTC is a biopharmaceutical company focused on the discovery, developmentand commercialization of orally administered, proprietary, small-moleculedrugs that target post-transcriptional control processes.Post-transcriptional control processes regulate the rate and timing of proteinproduction and are of central importance to proper cellular function. PTC'sinternally-discovered pipeline addresses multiple therapeutic areas, includinggenetic disorders, oncology and infectious diseases. In addition, PTC hasdeveloped proprietary technologies and extensive knowledge ofpost-transcriptional control processes that it applies in its drug discoveryand development activities, including the Gene Expression Modulation bySmall-molecules (GEMS) technology platform, which has been the basis forcollaborations with leading pharmaceutical and biotechnology companies such asGenzyme, Pfizer, Celgene, CV Therapeutics and Schering-Plough. For moreinformation, visit PTC's website, www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.